Yumiko Toda, Masahiro Ashizawa, Rui Murahashi, Hirotomo Nakashima, Takashi Ikeda, Shin-Ichiro Kawaguchi, Takashi Nagayama, Kento Umino, Daisuke Minakata, Kaoru Morita, Chihiro Yamamoto, Kaoru Hatano, Kazuya Sato, Shin-Ichiro Fujiwara, Ken Ohmine, Yoshinobu Kanda
Guidelines recommend rasburicase for high-risk patients to prevent tumor lysis syndrome (TLS). However, little information is available on the incidence and outcome of TLS in AML patients. We analyzed 145 patients with AML who underwent induction therapy before the approval of rasburicase to evaluate the incidence of TLS and the necessity of rasburicase as prophylaxis. Three patients had already developed clinical TLS (CTLS) at diagnosis of AML, and another three developed CTLS after the initiation of chemotherapy...
April 5, 2024: International Journal of Hematology